

Contents lists available at ScienceDirect

Progress in Biophysics and Molecular Biology

journal homepage: www.elsevier.com/locate/pbiomolbio



Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting*



Douglas B. Kell a, b, c, *, Etheresia Pretorius d, **

- ^a School of Chemistry, The University of Manchester, 131, Princess St, Manchester, M1 7DN, Lancs, UK
- ^b The Manchester Institute of Biotechnology, The University of Manchester, 131, Princess St, Manchester, M1 7DN, Lancs, UK
- ^c Centre for Synthetic Biology of Fine and Speciality Chemicals, The University of Manchester, 131, Princess St, Manchester, M1 7DN, Lancs, UK
- ^d Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia, 0007, South Africa

ARTICLE INFO

Article history: Received 22 May 2016 Received in revised form 14 August 2016 Accepted 19 August 2016 Available online 21 August 2016

Keywords: Amyloid Fibril Prion Blood clotting LPS Amplification

ABSTRACT

The chief and largely terminal element of normal blood clotting is considered to involve the polymerisation of the mainly α -helical fibrinogen to fibrin, with a binding mechanism involving 'knobs and holes' but with otherwise little change in protein secondary structure. We recognise, however, that extremely unusual mutations or mechanical stressing <u>can</u> cause fibrinogen to adopt a conformation containing extensive β -sheets. Similarly, prions can change morphology from a largely α -helical to largely β -sheet conformation, and the latter catalyses both the transition and the self-organising polymerisation of the β -sheet structures. Many other proteins can also do this, where it is known as amyloidogenesis. When fibrin is formed in samples from patients harbouring different diseases it can have widely varying diameters and morphologies. We here develop the idea, and summarise the evidence, that in many cases the anomalous fibrin fibre formation seen in such diseases actually amounts to amyloidogenesis. In particular, fibrin can interact with the amyloid- β (β) protein that is misfolded in Alzheimer's disease. Seeing these unusual fibrin morphologies as true amyloids explains a great deal about fibrin(ogen) biology that was previously opaque, and provides novel strategies for treating such coagulopathies. The literature on blood clotting can usefully both inform and be informed by that on prions and on the many other widely recognised (β -)amyloid proteins. A preprint has been lodged in bioRxiv (Kell and Pretorius, 2016).

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Contents

1.	Introduction: the thermodynamics of protein folding and prion proteins, and the existence of multiple macrostates	17
2.	The terminal stages of normal blood clotting: fibrinogen, fibrin and thrombin	19
3.	Methods for determining the clotting process	20
	3.1. Optical methods based on fluorescence and birefringence	
	3.2. Thioflavin S, thioflavin T and derivatives	22
	3.3. Luminescent conjugated thiophenes	24
4	The conversion of fibringen to fibring is normally not a transition from α -helices to β -sheets except in special circumstances that include mutat	

E-mail addresses: dbk@manchester.ac.uk (D.B. Kell), resia.pretorius@up.ac.za (E. Pretorius).

 $^{\,\,^{\}star}$ Paper number 9 in the series "a dormant blood microbiome in chronic, in-flammatory disease".

^{*} Corresponding author. The Manchester Institute of Biotechnology, The University of Manchester, 131, Princess St, Manchester, M1 7DN, Lancs, UK.

^{**} Corresponding author. Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia, 0007, South Africa.

5.	Mechanical stretching can induce an α -to- β transition in a large variety of biopolymers	. 24
	5.1. Effects of flow on fibrin properties	24
6.	When clotting goes wrong: hypercoagulability and hypofibrinolysis in chronic, inflammatory diseases	. 24
7.	Mutual effects of fibrin(ogen) on β -amyloid in Alzheimer's disease	. 25
8.	Small molecules that affect the nature of blood clotting and fibrin fibres in vitro	. 26
9.	Induction of amyloidogenic clotting by added LPS (endotoxin)	. 27
10.	Anomalous blood clotting involves genuine amyloid formation	. 27
11.	The extent of amplification of protein transitions by LPS can be mimicked by liquid crystals	. 27
12.	Chronic infection and amyloidogenesis	. 28
13.	Serum amyloid A	. 28
14.	Sequelae of amyloidogenesis	. 28
15.	Possible treatments for coagulopathies in the light of their role in amyloidogenesis	. 28
16.	Quo vadis? – systems strategies	. 29
	Acknowledgments	30
	Note added in proof	30
	References	. 30

"Novel but physiologically important factors that affect fibrinolysis have seldom been discovered and characterized in recent years" (Weisel, 2011)

1. Introduction: the thermodynamics of protein folding and prion proteins, and the existence of multiple macrostates

Starting with Anfinsen's famous protein re-folding experiments (Anfinsen, 1973; Anfinsen et al., 1961), showing that an unfolded protein would refold reliably to its commonest (and original) state as found in the cell, it was widely assumed that the normal macrostate of a folded protein was that of its lowest free energy.

If one allows each amino acid to have n distinct conformational substates, the total number $n^{\rm m}$ scales exponentially with the number m of amino acids (Kell, 2012), and until recently exhaustive calculations to determine whether the 'preferred' conformation was of lowest free energy were prohibitively expensive (Piana et al., 2014, 2012, 2013; Verma and Wenzel, 2009); indeed, they still are save for small proteins, so this question of whether the 'normal' conformation is that of lowest free energy (\pm kT) is certainly not settled in general terms, and (as we shall see in many cases) forms

Fig. 1. PrP^c conformation of human prion protein (1HJM at PDB).

of lower free energy than the 'normal' one are in fact both common and of high biological significance.

In particular, as is again well known (Aguzzi and Calella, 2009; Caughey et al., 2009; Colby and Prusiner, 2011; Prusiner, 1998), and starting with Virchow's observations in 1854 (Sipe and Cohen, 2000), a number of proteins of a given sequence can exist in at least two (or more) highly distinct conformations (e.g. (Chiti and Dobson, 2006; Eisenberg and Jucker, 2012)). Typically the normal ('benign') form, as produced initially within the cell, will have a significant α -helical content and a very low amount of β -sheet, but the abnormal ('rogue') form, especially when in the form of an insoluble amyloid (Dobson, 2013), will have a massively increased amount of β -sheet (Baldwin et al., 1994; Groveman et al., 2014; Harrison et al., 1997; Jack et al., 2006; Jahn et al., 2008; Pan et al., 1993) (but cf (Ow and Dunstan, 2014)), whether parallel or antiparallel (Tycko and Wickner, 2013). The canonical example is the prion protein PrPc, whose abnormal form is known as PrPSc, and whose PrPc structure is shown in Fig 1. As is also well known, the monomers of the abnormal form may catalyse their own formation from the normal form, and will typically go on to self-assemble to form oligomers, protofibrils and finally insoluble fibrils (Colby and Prusiner, 2011). (A particular hallmark of PrPSc, and indeed a common basis for its assay, is its very great resistance to proteolysis relative to PrPc, typically assessed using proteinase K (Basu et al., 2007; Grassi et al., 2000; Mishra et al., 2004; Saá and Cervenakova, 2015; Saleem et al., 2014; Saverioni et al., 2013; Silva et al., 2015)).




Fig. 2. Kinetic isolation of PrPSc from PrPC (based on (Cohen and Prusiner, 1998).

Download English Version:

https://daneshyari.com/en/article/5519929

Download Persian Version:

https://daneshyari.com/article/5519929

<u>Daneshyari.com</u>